Na, und hier kommt der ausführliche Quartals-Bericht Ende 2016, Q2/2017:
Die Aussichten sind doch positiv.
http://www.asx.com.au/asxpdf/20170127/pdf/43fkf46c61xd4q.pdf
Na, und hier kommt der ausführliche Quartals-Bericht Ende 2016, Q2/2017:
Die Aussichten sind doch positiv.
http://www.asx.com.au/asxpdf/20170127/pdf/43fkf46c61xd4q.pdf
Hallo Lorenz
Ich staune immer wieder über deinen Optimismus :)...auch wenn der Bericht positiv ist, es wird sich sehr wahrscheinlich im Kurs nichts tun...da braucht es schon was "handfestes"
....und welchem Umstand verdanken wir den netten Kursanstieg der letzten Tage...?
Gruss, Simona
*smile*
Ja, gell, kann nur sagen, man sollte halt immer etwas GENE haben. Wenn sie dann plötzlich mega abheben ist man dabei. Das hatten wir schon öfters. Wünsche allen gutes Gelingen und mit allen meine ich natürlich und vor allem auch GENE!
Grüsse euch aus den Ferien, die bald vorbei sind,
euer
Was für einen netten Kursanstieg?? Da ist weiterhin gar nichts los
Nebenbei bemerkt, Höchst war heute 1.38. *new_russian*
Da gibt es auch mal wieder positve News, heute:
http://www.asx.com.au/asxpdf/20170329/pdf/43h3yfv4vyg4l8.pdf
Presse:
The IndyCar racing driver is serving for a second consecutive term.
[Blockierte Grafik: http://www.proactiveinvestors.com.au/thumbs/upload/News/Image/2017_03/757z468_shutterstock_439844257.jpg]
Genetic Technologies is focused on the U.S. market
Genetic Technologies (ASX:GTG) has signed IndyCar racing driver Ms. Pippa Mann to promote BREVAGenplus®, the company’s risk assessment test for non-hereditary breast cancer.
Genetic Technologies is continuing its U.S. focused marketing program for BREVAGenplus, with Pippa Mann serving for a second consecutive term as the product’s ambassador and spokesperson.
The test assesses both clinical risk factors and genetic markers known to be associated with non-hereditary breast cancer to determine a woman's five-year risk of developing the disease.
Genetic’s key partnership activities with Pippa Mann this year will include the BREVAGenplus logo represented on her #63 Dale Coyne Racing car and promotional apparel.
She will also participate at select BREVAGenplus oriented events and other promotional activities over the course of 2017.
Pippa Mann is one of only nine female athletes to ever compete in the “Indy 500” and the only female driver to start in the race over the past four consecutive years.
In December 2016, Genetic raised $8.1 million from professional and sophisticated investors in the U.S.
The funds raised will be used to facilitate the company’s expansion requirements in relation to BREVAGenplus and the development of a colorectal cancer risk assessment test.
Breast cancer affects 1 in 8 women in their lifetime. Each year over 240,000 new cases of breast cancer are diagnosed in the U.S.
Quelle:
Ich sehe da auch grad noch eine neue Info, könnte was bringen, die Änderung im Zahlungsmodus:
http://www.asx.com.au/asxpdf/20170331/pdf/43h5nrnhltnnvd.pdf
Gruss, Simona
ich sehe, Ihr gebt die Hoffnung nicht auf :)...
@ Simona
Kommt offenbar an, ja.
Q3-2016/17, per 31. März 2017
https://www.sec.gov/Archives/e…04659-17-026673-index.htm
http://stockmarket.hobsonwealt…item?S=GTG&E=ASX&N=469209
Wünsche guten Erfolg.
@ GENE *help*
Welchem Umstand verdanken wir diesen Kursrückgang? Ist das Euer Sommer-Sonderverkauf?! Wir haben Sommer hier. Recht unterschiedliches T-Shirt und Long-Shirt-Wetter, aber ohne Reverse-Split.-
Holt gefälligst den Kurs rauf. Wir machen keine Repetition.
Besser als gedacht: Mehr Tests im Quartal, Kosten reduziert, bessere Aussichten...
http://news.iguana2.com/macquaries/ASX/GTG/474017
Vielleicht werden wir mal noch profitabel?
Hier noch vom 21.09.17 News/Infos und
@GENE
Was wurde aus den Darmkrebs-Test??
http://news.iguana2.com/macquaries/ASX/GTG/478233
Info
Geschäftsbericht: und Generalversammlung
https://www.sec.gov/Archives/e…197/a17-24326_1ex99d1.htm:
Wann sehen wir die Quartalszahlen?
So, nun müsst ihr nur noch den Kurs raufziehen.
http://news.iguana2.com/macquaries/ASX/GTG/481154
https://www.sec.gov/Archives/e…7063197/a17-24326_16k.htm
https://www.sec.gov/Archives/e…04659-17-063197-index.htm
Gruss, Simona
Wird das nun eine Übernahme?
Genetic Tech up 11% on takeover interest
Dec. 12, 2017 11:58 AM ET|By: Douglas W. House, SA News Editor
Thinly traded nano cap Genetic Technologies (GENE +10.7%) is up more than double normal volume after it announced that potential suitors made presentations to the Chairman and CEO in late November.
In August, it announced that it had initiated a review of strategic alternatives, including an outright sale of the company.
Previously: Genetic Technologies announces comprehensive review of strategic alternatives (Aug. 25)
[Blockierte Grafik: https://static.seekingalpha.com/assets/og_image_410-b8960ce31ec84f7f12dba11a09fc1849b69b234e0f5f39d7c62f46f8692e58a5.png]
1,065 people get GENE breaking news and analysis by email alert
EX-99.1 2 a17-28325_1ex99d1.htm EX-99.1
Exhibit 99.1
[Blockierte Grafik: https://www.sec.gov/Archives/edgar/data/1166272/000110465917072872/g283251mmi001.jpg]
ASX ANNOUNCEMENT
12 December 2017
Genetic Technologies Provides Update on Strategic Review Initiative
Melbourne, Australia, 12 December 2017: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), a molecular diagnostics company focused on cancer risk assessment, and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for non-hereditary breast cancer, is pleased to report that it has entered an important stage of the Company’s strategic review which was announced to the market on 25 August 2017.
At that time, the Company announced the engagement of Roth Capital Partners, LLC (Roth) a U.S. based corporate advisory firm to launch a comprehensive strategic review initiative with a clear mandate to explore a wide range of possible strategic opportunities for the Company and its assets - designed to maximise near and long-term value for the shareholders.
Since their appointment, Roth has conducted a confidential market out-reach program to identify potential interested parties. Following what was an intensive and systematic screening process, a target short list was prepared, with the shortlisted targets invited to present to the Company’s Chairman and Chief Executive Officer. The presentations took place in New York during the week commencing 27 November 2017; each party having expressed significant interest in the Company and its assets.
The Company remains in active discussions with multiple parties regarding a potential transaction(s) as those short listed interested parties now continue their due diligence. The Board remains committed to the strategic review and will carefully consider all alternatives and make a decision that reflects the best interest of all shareholders.
However, as advised to the market, the Company is in receipt of a Section 249D notification requesting a shareholder meeting and with proposed resolutions for the removal of current Board members: Dr. Malcolm R Brandon, Mr. Grahame Leonard and Mr. Eutillio Buccilli and appointment of nominees by the requisitioning shareholders. Accordingly there can be no assurance as to whether or not any transaction arising out of the Roth strategic review will take place, the structure of any such potential transaction, or the ultimate timing. In part this may depend upon the results of the shareholder meeting to be convened to consider the change in the Company’s board composition.
Genetic Technologies Limited · Website: http://www.gtglabs.com · Email: info@gtglabs.com ABN 17 009 212 328
Registered Office · 60-66 Hanover Street Fitzroy Victoria 3065 Australia · Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 · Fax +61 3 8412 7040
FOR FURTHER INFORMATION PLEASE CONTACT
Mr. Eutillio Buccilli |
Jason Wong (USA) |
Executive Director & Chief Executive Officer |
Blueprint Life Science Group |
Genetic Technologies Limited |
+ 1 (415) 375 3340, Ext. 4 |
+ 61 3 8412 7050 |
|
Eric Cheng (USA) |
|
Managing Director |
|
Roth Capital Partners |
|
+ 1 (646) 358 1901 |
About Genetic Technologies Limited
Genetic Technologies is a molecular diagnostics company that offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGenplus is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer.
The Company markets BREVAGenplus, through its U.S. subsidiary Phenogen Sciences Inc., to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons). For more information, please visit http://www.brevagenplus.com and http://www.phenogensciences.com.
Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit http://www.gtgcorporate.com
About Roth Capital Partners
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, California, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit http://www.roth.com.
Safe Harbor Statement
Any statements in this press release that relate to the Company’s expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results. Additional risks associated with Genetic Technologies’ business can be found in its periodic filings with the SEC.
Es schaut ganz danach aus. Hoffe natürlich auf einen superschönen Kurs... *smile* *dirol*
(Sorry für die verspätete Antwort, hier war das Forum offenbar gestört).